Early Change in the Plasma Levels of Circulating Soluble Immune Checkpoint Proteins in Patients with Unresectable Hepatocellular Carcinoma Treated by Lenvatinib or Transcatheter Arterial Chemoembolization
暂无分享,去创建一个
A. Tamori | A. Hagihara | N. Kawada | L. Thuy | Kohei Kotani | M. Enomoto | S. Uchida-Kobayashi | Naoshi Odagiri | H. Hai | Minh Phuong Dong | M. Suoh
[1] Yulei N. Wang,et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. , 2020, The New England journal of medicine.
[2] R. Masuzaki,et al. Different Mechanisms of Action of Regorafenib and Lenvatinib on Toll-Like Receptor-Signaling Pathways in Human Hepatoma Cell Lines , 2020, International journal of molecular sciences.
[3] A. Tamori,et al. Clinical significance of circulating soluble immune checkpoint proteins in sorafenib-treated patients with advanced hepatocellular carcinoma , 2020, Scientific Reports.
[4] M. Kudo,et al. Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Subgroup analyses from CheckMate 040. , 2020 .
[5] N. Chalasani,et al. Immune Checkpoint Axes Are Dysregulated in Patients With Alcoholic Hepatitis , 2020, Hepatology communications.
[6] A. Jemal,et al. Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.
[7] K. Malagari,et al. Association of TIM-3 with BCLC Stage, Serum PD-L1 Detection, and Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma , 2020, Cancers.
[8] R. Berger,et al. Checkpoint Genes at the Cancer Side of the Immunological Synapse in Bladder Cancer , 2019, Translational oncology.
[9] Xifeng Wu,et al. Soluble immune checkpoint-related proteins as predictors of tumor recurrence, survival, and T cell phenotypes in clear cell renal cell carcinoma patients , 2019, Journal of Immunotherapy for Cancer.
[10] V. Longo,et al. Role of BRAF in Hepatocellular Carcinoma: A Rationale for Future Targeted Cancer Therapies , 2019, Medicina.
[11] J. Shindoh,et al. 18F-Fluorodeoxyglucose Uptake in Hepatocellular Carcinoma as a Useful Predictor of an Extremely Rapid Response to Lenvatinib , 2019, Liver Cancer.
[12] Ming Luo,et al. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma , 2019, Journal of experimental & clinical cancer research : CR.
[13] Mohammad Hossein Khosravi,et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017 , 2019, JAMA oncology.
[14] V. Longo,et al. Emerging Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma , 2019, Medicina.
[15] T. Murakami,et al. Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH‐HCC guidelines) 2019 update , 2019, Hepatology research : the official journal of the Japan Society of Hepatology.
[16] V. Longo,et al. Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib , 2019, Medicina.
[17] V. Longo,et al. Immune system and bone microenvironment: rationale for targeted cancer therapies , 2019, Oncotarget.
[18] M. Kudo,et al. Nivolumab in Advanced Hepatocellular Carcinoma: Sorafenib-Experienced Asian Cohort Analysis. , 2019, Journal of hepatology.
[19] Peng Zhang,et al. Trends in the treatment of advanced hepatocellular carcinoma: immune checkpoint blockade immunotherapy and related combination therapies. , 2019, American journal of cancer research.
[20] M. Kudo,et al. Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study , 2019, Cancers.
[21] A. Azzariti,et al. Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot Study , 2019, Cancers.
[22] M. Kudo,et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.
[23] M. Abecassis,et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases , 2019, Clinical Liver Disease.
[24] Xiang Xu,et al. Soluble immune checkpoints in cancer: production, function and biological significance , 2018, Journal of Immunotherapy for Cancer.
[25] M. Kudo. Systemic Therapy for Hepatocellular Carcinoma: Latest Advances , 2018, Cancers.
[26] Chiun Hsu,et al. Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy , 2018, Seminars in Liver Disease.
[27] F. Hirsch,et al. TIM-3, a promising target for cancer immunotherapy , 2018, OncoTargets and therapy.
[28] M. Cutolo,et al. A circulating cell population showing both M1 and M2 monocyte/macrophage surface markers characterizes systemic sclerosis patients with lung involvement , 2018, Respiratory Research.
[29] A. Tamori,et al. Changes in plasma interleukin-8 and tumor necrosis factor-α levels during the early treatment period as a predictor of the response to sorafenib in patients with unresectable hepatocellular carcinoma , 2018, Cancer Chemotherapy and Pharmacology.
[30] M. Abecassis,et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases , 2018, Hepatology.
[31] Gisela Schwab,et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma , 2018, The New England journal of medicine.
[32] M. Kudo,et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. , 2018, The Lancet. Oncology.
[33] P. Schirmacher,et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.
[34] M. Kudo,et al. Immune checkpoint blockade for the treatment of human hepatocellular carcinoma , 2018, Hepatology research : the official journal of the Japan Society of Hepatology.
[35] M. Kudo,et al. A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC). , 2018 .
[36] M. Kudo,et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial , 2018, The Lancet.
[37] Alan D. Lopez,et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study , 2017, JAMA oncology.
[38] S. Steinberg,et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. , 2017, Journal of hepatology.
[39] Masatoshi Kudo,et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.
[40] J. Zhao,et al. Soluble costimulatory molecule sTim3 regulates the differentiation of Th1 and Th2 in patients with unexplained recurrent spontaneous abortion. , 2015, International journal of clinical and experimental medicine.
[41] J. Wands,et al. Aspartate-β-hydroxylase induces epitope-specific T cell responses in hepatocellular carcinoma. , 2015, Vaccine.
[42] B. Sangro,et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] Masao Iwata,et al. Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models , 2014, Journal of thyroid research.
[44] E. Tartour,et al. Control of the Immune Response by Pro-Angiogenic Factors , 2014, Front. Oncol..
[45] E. Gostick,et al. Immunodominance and functional alterations of tumor‐associated antigen‐specific CD8+ T‐cell responses in hepatocellular carcinoma , 2014, Hepatology.
[46] I. Mellman,et al. Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.
[47] S. Steinberg,et al. Soluble CD27-Pool in Humans May Contribute to T Cell Activation and Tumor Immunity , 2013, The Journal of Immunology.
[48] Y. Kanda,et al. Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.
[49] Brett Houser,et al. Bio-Rad’s Bio-Plex® suspension array system, xMAP technology overview , 2012, Archives of physiology and biochemistry.
[50] Pedro M. Valero-Mora,et al. ggplot2: Elegant Graphics for Data Analysis , 2010 .
[51] S. Kawasaki,et al. The committee for revision of the Clinical Practice Guidelines for Hepatocellular Carcinoma , 2010 .
[52] S. Paggi,et al. Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .
[53] Dieter Häussinger,et al. Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.
[54] P. Twomey,et al. Plasma glucose measurement with the Yellow Springs Glucose 2300 STAT and the Olympus AU640 , 2004, Journal of Clinical Pathology.
[55] S. Boerner. The Cytology of Soft Tissue Tumours , 2004 .
[56] T. Schumacher,et al. CD27 is required for generation and long-term maintenance of T cell immunity , 2000, Nature Immunology.
[57] M. Dumont,et al. European Association for the Study of the Liver , 1971 .
[58] Junnian Zheng,et al. Lenvatinib promotes antitumor immunity by enhancing the tumor infiltration and activation of NK cells. , 2019, American journal of cancer research.
[59] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[60] P. Twomey,et al. Limitations of the Wilcoxon matched pairs signed ranks test for comparison studies. , 2004, Journal of clinical pathology.
[61] Ranjeny Thomas,et al. CD40 and dendritic cell function. , 2003, Critical reviews in immunology.
[62] J. Bruix,et al. Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification , 1999, Seminars in liver disease.